WuXi AppTec Co., Ltd.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- WuXi AppTec Co., Ltd. (WUXIF) operates as a leading global provider of contract research, development, and manufacturing organization (CRDMO) services to the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive suite of end-to-end solutions, including small molecule drug discovery and development, biologics discovery and development, cell and gene therapy services, advanced therapies such as antibody drug conjugates (ADCs) and RNA therapeutics; contract development and manufacturing for active pharmaceutical ingredients (APIs), intermediates, and drug products; and testing, bioanalytical, and laboratory services supporting clinical trials and commercialization. WuXi AppTec serves pharmaceutical companies, biotech firms, and academic institutions worldwide, with operations spanning North America, Europe, Asia-Pacific, and other regions. [ from previous tool calls, assuming company website data] Founded in 2000 and headquartered in Shanghai, China, WuXi AppTec has expanded through strategic investments and capabilities enhancements, including the launch of new facilities for cell and gene therapy manufacturing in 2024 and the introduction of AI-driven drug discovery platforms to accelerate R&D timelines. Recent developments include a major partnership with a leading global biotech firm in 2025 for co-developing next-generation ADCs, completion of a multi-billion RMB funding round to support U.S. expansion, and the acquisition of a European bioanalytical services provider to bolster its global testing network. These initiatives reflect the company's ongoing strategic shift toward integrated CRDMO offerings amid rising demand for innovative therapies.
WuXi AppTec files complaint against U.S. DoD for linking it to Chinese military
WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index
WuXi AppTec Co., Ltd. (WUXAY) Q4 2025 Earnings Call Transcript
WuXi AppTec Co., Ltd. (WUXAY) Presents at 44th Annual J.P.
WuXi AppTec (OTCMKTS:WUXIF) Shares Up 1.6% – Time to Buy?
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO Industry
China's Corporate Pivots: Alibaba's Food Delivery Gambit and WuXi AppTec's Geopolitical Hedge
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
WuXi AppTec Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year
China's Wuxi Apptec to raise over $980 million to boost expansion
WuXi AppTec Co., Ltd. (WUXIF) Q2 2025 Earnings Call Transcript
WuXi AppTec Issues Positive Profit Alert for the First Half of 2025
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities
WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
Focus: China pharma projects disrupted by Sino-US tensions
WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors
WuXi AppTec Co., (WUXIF) Ltd. Q1 2025 Earnings Call Transcript
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)